Rare Case Links Cancer Immunotherapy Drug to Sudden-Onset Type 1 Diabetes

A 71-year-old woman undergoing cancer treatment with atezolizumab—an immune checkpoint inhibitor used for neuroendocrine carcinoma—developed type 1 diabetes with dangerous speed. Within days, her blood glucose climbed to 1,435 mg/dL and she showed signs of diabetic ketoacidosis, a life-threatening metabolic crisis. What made this case unusual was what imaging revealed: doctors could see pancreatic inflammation on a CT scan taken two days *before* she showed any symptoms.

Computed tomography performed on the day before the patient's clinical presentation revealed enlargement of the pancreatic tail and increased inflammation in surrounding tissues. The pancreas had swollen from a baseline volume of 46 milliliters to 82.5 milliliters. By the day she was diagnosed with diabetes, the swelling had largely resolved. Six months later, the pancreas had shrunk further, to 39 milliliters, reflecting permanent loss of tissue.

This progression—from inflammation to shrinkage—provides a window into how immune checkpoint inhibitors can damage the insulin-producing cells. The imaging changes happened rapidly and were visible before the patient experienced severe symptoms.

Type 1 diabetes triggered by immune checkpoint inhibitors is rare but can be life-threatening. Early detection could allow faster intervention. This case report suggests that pancreatic enlargement or inflammatory changes seen on imaging during immunotherapy might serve as an alert, though much more research is needed to confirm whether imaging findings predict diabetes onset.

Patients receiving immune checkpoint inhibitors should remain aware of symptoms such as nausea, appetite loss, or unusual thirst and should report them promptly to their care team. This case is a single example and does not establish a diagnostic rule; it is meant to inform future research, not guide individual medical decisions.

This is a hypothesis-generating case report based on one patient's experience. It does not prove that all patients with pancreatic enlargement during immunotherapy will develop diabetes, nor does it show how common this imaging finding is. Larger studies are needed to determine whether screening for pancreatic changes could help identify patients at highest risk and whether earlier detection would improve outcomes.

Source: Endocrine journal. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.